ROGAINE (FOR WOMEN)
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ROGAINE (FOR WOMEN) (ROGAINE (FOR WOMEN)).
Minoxidil is a potassium channel opener. It causes vasodilation by opening ATP-sensitive potassium channels in vascular smooth muscle cells, leading to hyperpolarization and relaxation of arteriolar smooth muscle. This improves blood flow to hair follicles and prolongs the anagen phase of hair growth, possibly by increasing vascular endothelial growth factor (VEGF) and other growth factors.
| Metabolism | Minoxidil is primarily metabolized in the liver via glucuronidation to minoxidil glucuronide, which is inactive. Minor metabolism via sulfation may occur. The metabolism is mediated by UDP-glucuronosyltransferases (UGTs). |
| Excretion | Renal excretion of unchanged minoxidil and its glucuronide conjugates accounts for approximately 95% of the absorbed dose; about 5% is eliminated unchanged in feces via biliary excretion. |
| Half-life | The terminal elimination half-life of minoxidil is approximately 4.2 hours (range 2–7 hours) following topical application, but the pharmacodynamic half-life (duration of drug presence in the skin and hair follicle) is longer, estimated at 24 hours. For oral minoxidil, the terminal half-life averages 4.5 hours (range 3–7 hours). |
| Protein binding | Minoxidil is approximately 20% bound to serum proteins, primarily albumin, with negligible binding to alpha-1-acid glycoprotein. |
| Volume of Distribution | The apparent volume of distribution for minoxidil is 3.5 L/kg (range 2.5–4.5 L/kg), indicating extensive extravascular distribution and tissue binding, particularly to vascular smooth muscle. |
| Bioavailability | Absolute bioavailability of topical minoxidil is approximately 1.5% (range 0.3–3.2%) of the applied dose, due to low percutaneous absorption and extensive first-pass metabolism in the skin. Oral minoxidil has an absolute bioavailability of 90%. |
| Onset of Action | For topical minoxidil (5% solution marketed as Rogaine for Women), onset of hair regrowth is typically observed after 4–8 months of twice-daily application; some patients may notice initial shedding within 2–6 weeks. |
| Duration of Action | After discontinuation of topical minoxidil, hair regrowth effects begin to reverse within 3–4 months, and baseline hair loss pattern returns within 6–12 months. Continuous use is required to maintain benefit. |
Apply 1 mL of 2% minoxidil solution topically to the scalp twice daily (total 2 mL per day).
| Dosage form | SOLUTION |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No dosage adjustment required for hepatic impairment. |
| Pediatric use | Safety and efficacy not established; use is not recommended. |
| Geriatric use | No specific dose adjustment; use with caution due to potential increased sensitivity. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ROGAINE (FOR WOMEN) (ROGAINE (FOR WOMEN)).
| Breastfeeding | Minoxidil is excreted in human milk following oral administration; however, data after topical use are lacking. The milk-to-plasma ratio (M/P) is unknown for topical application. Due to potential for adverse effects in the nursing infant (e.g., hypotension), breastfeeding is not recommended during treatment. |
| Teratogenic Risk | Topical minoxidil (Rogaine for Women) has limited human pregnancy data. Animal studies show no teratogenic effects at systemic exposures up to 5 times the human topical dose. Systemic absorption is minimal (<1.5%) with recommended topical use, but it is classified as pregnancy category C. First trimester: theoretical risk, avoid use. Second and third trimesters: minimal known risk but use only if clearly needed. |
■ FDA Black Box Warning
None for topical minoxidil (Rogaine for Women). Oral minoxidil (not this formulation) carries a boxed warning for adverse cardiovascular effects.
| Serious Effects |
["Hypersensitivity to minoxidil or any component of the formulation","Use on broken, irritated, or sunburned scalp","Concomitant use with other topical agents that may increase absorption (e.g., corticosteroids, tretinoin)","Relative: Pregnancy and breastfeeding (minoxidil is pregnancy category C; use only if benefit outweighs risk)"]
| Precautions | ["Systemic absorption can cause cardiovascular effects such as tachycardia, fluid retention, and hypotension (rare with topical use)","May cause local skin reactions: irritation, redness, itching, or dryness","Potential for increased hair loss initially (shedding of telogen hairs) during first 2-6 weeks","Avoid contact with eyes, mucous membranes, and broken skin","Use caution in patients with underlying cardiovascular disease (angina, arrhythmias, heart failure)","Discontinue if systemic side effects occur or if no improvement after 6 months"] |
Loading safety data…
| Fetal Monitoring | No specific maternal or fetal monitoring is routinely required for topical minoxidil use in pregnancy. However, consider monitoring maternal blood pressure and heart rate if signs of systemic absorption (e.g., dizziness, tachycardia) occur. Fetal growth may be assessed if there is concern for systemic effects. |
| Fertility Effects | Limited data. Oral minoxidil has been associated with reduced sperm motility in some animal studies, but topical use is unlikely to impact fertility due to low systemic absorption. No significant effects on female fertility have been reported. |